Abstract
Background: Diabetes mellitus (DM) is one of the major risk factors contributing to Acute Coronary Syndromes (ACS) and is associated with an increased risk of adverse clinical outcomes following percutaneous coronary intervention (PCI), even when the second generation of drug-eluting stents (DES) is used. In order to overcome the disadvantages of permanent caging of a vessel with metallic DES, bioresorbable scaffold (BRS) technology has been recently developed. However, the prognosis of patients with DM and ACS treated with PCI via subsequent implantation of Magmaris (Biotronik, Berlin, Germany)—a novel magnesium-bioresorbable scaffold—is poorly investigated. Methods: A total of 193 consecutive subjects with non-ST elevation acute coronary syndrome (NSTE-ACS) who, from October 2016 to March 2020, received one or more Magmaris scaffolds were enrolled in this study. The diabetic group was compared with non-diabetic subjects. Results: There were no significant differences in the occurrence of primary endpoints (cardiovascular death, myocardial infarction, and in-stent thrombosis) and principal secondary endpoints (target-lesion failure, scaffold restenosis, death from any reason, and other cardiovascular events) between the two compared groups in a 1-year follow-up period. Conclusions: The early 1-year-outcome of magnesium bioresorbable scaffold (Magmaris) seems to be favorable and suggests that this novel BRS is safe and effective in subjects with NSTE-ACS and co-existing DM.
Highlights
The new generation of drug-eluting stents improved the outcomes of percutaneous coronary intervention (PCI), there is still a higher rate of major cardiovascular adverse events in diabetic patients [2], which is related to a disturbance in the artery healing caused by the presence of a metallic scaffold in the lumen of the vessel
The study population was selected out of all consecutive patients with Acute Coronary Syndromes (ACS) who qualified for PCI at the department
ACS underwent PCI with 74 bioresorbable scaffold (BRS) implantation, of which 58 (80.5%) patients were treated with oral medication and 14 (19.5%) patients were treated with insulin
Summary
The new generation of drug-eluting stents improved the outcomes of percutaneous coronary intervention (PCI), there is still a higher rate of major cardiovascular adverse events in diabetic patients [2], which is related to a disturbance in the artery healing caused by the presence of a metallic scaffold in the lumen of the vessel. It results in the activation of a chronic local inflammation and abnormalities in the vessel architecture with coexisting impairments in vasomotor function [3,4].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
